CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $1,013,472.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, December 2nd, Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $55.10, for a total value of $826,500.00.

CRISPR Therapeutics Stock Down 5.0 %

CRSP stock opened at $47.91 on Monday. The company has a market cap of $4.11 billion, a P/E ratio of -10.96 and a beta of 1.67. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $91.10. The business’s fifty day moving average is $42.25 and its 200-day moving average is $46.03.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRSP has been the topic of a number of research analyst reports. JMP Securities restated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Chardan Capital decreased their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $74.40.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its stake in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after buying an additional 1,474,439 shares during the period. Capital International Investors increased its holdings in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after purchasing an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. State Street Corp increased its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Finally, FMR LLC increased its holdings in CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after purchasing an additional 23,075 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.